JavaScript is disabled in your browser. Please enable JavaScript to view this website.
AB43050

Recombinant VZV gE protein

Be the first to review this product! Submit a review

|

(2 Publications)

Recombinant VZV gE protein is a Fragment protein, in the 48 to 135 aa range, expressed in Escherichia coli, with >95%, suitable for ELISA, WB.

View Alternative Names

ORF68, Envelope glycoprotein E

Key facts

Purity

>95% SDS-PAGE

Expression system

Escherichia coli

Tags

GST tag N-Terminus

Applications

ELISA, WB

applications

Biologically active

No

Animal free

No

Carrier free

No

Storage buffer

Constituents: 50% Glycerol (glycerin, glycerine), 0.395% Tris HCl, 0.0292% EDTA

storage-buffer

Reactivity data

{ "title": "Reactivity Data", "filters": { "stats": ["", "Reactivity", "Dilution Info", "Notes"] }, "values": { "ELISA": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" }, "WB": { "reactivity":"TESTED_AND_REACTS", "dilution-info":"", "notes":"<p></p>" } } }

Sequence info

[{"sequence":"","proteinLength":"Fragment","predictedMolecularWeight":"35.6 kDa","actualMolecularWeight":null,"aminoAcidEnd":135,"aminoAcidStart":48,"nature":"Recombinant","expressionSystem":"Escherichia coli","accessionNumber":null,"tags":[{"tag":"GST","terminus":"N-Terminus"}]}]

Properties and storage information

Shipped at conditions
Blue Ice
Appropriate short-term storage conditions
-20°C
Appropriate long-term storage conditions
-20°C
False

Specifications

Form

Liquid

Additional notes

Sepharose derived purification.

General info

Product protocols

Publications (2)

Recent publications for all applications. Explore the full list and refine your search

Vaccines 11: PubMed38006010

2023

Pre-Clinical Development of an Adenovirus Vector Based RSV and Shingles Vaccine Candidate.

Applications

Unspecified application

Species

Unspecified reactive species

Lawrence Petherbridge,Charlotte Davis,Angela Robinson,Thomas Evans,Sarah Sebastian

Science translational medicine 15:eadf6598 PubMed37672567

2023

Humoral immunity to an endemic coronavirus is associated with postacute sequelae of COVID-19 in individuals with rheumatic diseases.

Applications

Unspecified application

Species

Unspecified reactive species

Jonathan D Herman,Caroline Atyeo,Yonatan Zur,Claire E Cook,Naomi J Patel,Kathleen M Vanni,Emily N Kowalski,Grace Qian,Shruthi Srivatsan,Nancy A Shadick,Deepak A Rao,Benjamin Kellman,Colin J Mann,Douglas Lauffenburger,Zachary S Wallace,Jeffrey A Sparks,Galit Alter
View all publications

Product promise

We are committed to supporting your work with high-quality reagents, and we're here for you every step of the way. In the unlikely event that one of our products does not perform as expected, you're protected by our Product Promise.
For full details, please see our Terms & Conditions

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.

For licensing inquiries, please contact partnerships@abcam.com